Efficacy of Tyrosine Kinase Inhibitors in ALK and EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases
Medical Sciences · 2025
DOI: 10.3390/medsci13030200 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medical Sciences, 2025. Verfasst von Walid Shalata und 12 weiteren Autor:innen. Beteiligte Einrichtung: The Legacy Heritage Cancer Center, Dr. Larry Norton Institute, Soroka Medical Center, Beer-Sheva 8410501, Israel. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Anaplastic Lymphoma Kinase, Brain Neoplasms, Protein Kinase Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Brain metastases (BMs) are a common and challenging complication of non-small cell lung cancer (NSCLC), historically associated with a poor prognosis. The development of targeted therapies, specifically tyrosine kinase inhibitors (TKIs) for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) gene alterations, has significantly improved treatment outcomes.
Methods
This article reports and evaluates the efficacy of different generations of TKIs for NSCLC with BMs. The primary endpoints assessed are intracranial objective response rates (IC-ORR), progression-free survival (PFS), and overall survival (OS). The analysis considers TKIs as monotherapy and in combination with radiotherapy. It also examines the impact of newer generation TKIs with enhanced blood–brain barrier (BBB) penetration on intracranial control. The report further discusses the integration of systemic therapy with local modalities like stereotactic radiosurgery (SRS) and the safety profiles of these agents, including central nervous system (CNS) and metabolic adverse events.
Results
Newer generation TKIs demonstrate significantly enhanced BBB penetration, resulting in superior intracranial control compared to older generations. These agents show remarkable intracranial activity, contributing to improved IC-ORR, PFS, and OS. The optimal integration of systemic therapy with local modalities, such as SRS, is still under investigation. Treatment with these TKIs is associated with distinct safety profiles, including novel CNS and metabolic adverse events, which require careful management due to prolonged treatment durations.
Conclusions
The management of CNS metastases in NSCLC is evolving towards more proactive and personalized therapeutic strategies. Newer generation TKIs have profoundly reshaped the treatment landscape by offering superior intracranial control. Further research is needed to determine the optimal integration of these systemic therapies with local modalities and to effectively manage the associated adverse events.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Legacy Heritage Cancer Center, Dr. Larry Norton Institute, Soroka Medical Center, Beer-Sheva 8410501, Israel.
- Goldman Medical School, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel.
- Neurosurgery Department, Soroka Medical Center, Beer-Sheva 8410501, Israel.
- Neurosurgery Department, Hadassah Hebrew University Medical Center, Jerusalem 91200, Israel.
- The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa 31096, Israel.
- Oncology Department, Bnai Zion Medical Center, Haifa 3104701, Israel.
ORCID-Profile: Walid Shalata, Rashad Naamneh, Wenad Najjar, Mahmoud Abu Amna, Abed Agbarya, Keren Rouvinov
Zitieren
APA
Shalata, W., Naamneh, R., Najjar, W., Abu Amna, M., Asla, M., Agbarya, A., Brenner, R., Abu Jama, A., Abu Yasin, N., Abu Juda, M., Abu Zeid, E. E. D., Rouvinov, K., & Yakobson, A. (2025). Efficacy of Tyrosine Kinase Inhibitors in ALK and EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases. Medical Sciences. https://doi.org/10.3390/medsci13030200
Vancouver
Shalata W, Naamneh R, Najjar W, Abu Amna M, Asla M, Agbarya A, et al. Efficacy of Tyrosine Kinase Inhibitors in ALK and EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases. Medical Sciences. 2025. doi:10.3390/medsci13030200
BibTeX
@article{Shalata2025,
author = {Shalata, Walid and Naamneh, Rashad and Najjar, Wenad and Abu Amna, Mahmoud and Asla, Mohnnad and Agbarya, Abed and Brenner, Ronen and Abu Jama, Ashraf and Abu Yasin, Nashat and Abu Juda, Mhammad and Abu Zeid, Ez El Din and Rouvinov, Keren and Yakobson, Alexander},
title = {Efficacy of Tyrosine Kinase Inhibitors in ALK and EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases},
journal = {Medical Sciences},
year = {2025},
doi = {10.3390/medsci13030200}
}
EUVIMED